Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - XML Representation

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="179619"/>
  <meta>
    <versionId value="5"/>
    <lastUpdated value="2025-03-15T21:15:32.464Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"/>
  </meta>
  <text>
    <status value="empty"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Brian S. Alper"/>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as">
    <valueMarkdown
                   value="SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-06. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619#json."/>
  </extension>
  <url value="https://fevir.net/resources/Group/179619"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="urn:ietf:rfc:3986"/>
    <value value="https://fevir.net/FOI/179619"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name
        value="SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer"/>
  <title
         value="SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="**Study selection criteria**
Types of Studies.
Randomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.

Types of participants.
Patients aged ≥18 years with cytological or histological diagnosis of mHNPC."/>
  <useContext>
    <code>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="evidence-communication"/>
      <display value="Evidence Communication"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="SystematicReviewEligibilityCriteria"/>
        <display value="SystematicReviewEligibilityCriteria"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <membership value="conceptual"/>
  <combinationMethod value="all-of"/>
  <characteristic>
    <code>
      <text value="Study Design"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/sevco"/>
        <code value="SEVCO:01003"/>
        <display value="randomized assignment"/>
      </coding>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="Randomized controlled clinical trials (RCTs)"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Study Design"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/sevco"/>
        <code value="SEVCO:01011"/>
        <display value="Parallel cohort design"/>
      </coding>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="parallel design"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Comparison"/>
    </code>
    <valueReference>
      <type value="EvidenceVariable"/>
      <display value="GroupAssignment: ADT plus docetaxel vs. ADT alone"/>
    </valueReference>
    <exclude value="false"/>
    <description
                 value="compared the association of ADT and chemotherapy (docetaxel), versus ADT alone"/>
  </characteristic>
  <characteristic>
    <code>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="397669002"/>
        <display value="Age"/>
      </coding>
    </code>
    <valueQuantity>
      <value value="18"/>
      <comparator value="&gt;="/>
      <unit value="years"/>
      <system value="http://unitsofmeasure.org"/>
      <code value="a"/>
    </valueQuantity>
    <exclude value="false"/>
    <description value="Types of participants.
Patients aged ≥18 years"/>
    <method>
      <text value="applied to participants in the studies"/>
    </method>
  </characteristic>
  <characteristic>
    <code>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="64572001"/>
        <display value="Disease (disorder)"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <text value="metastatic hormone-naive prostate cancer"/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description
                 value="Types of participants.
Patients with cytological or histological diagnosis of mHNPC."/>
    <method>
      <text value="applied to participants in the studies"/>
    </method>
    <method>
      <text value="cytological or histological diagnosis"/>
    </method>
  </characteristic>
</Group>